ANDA 75800, held by PharmoBedient. Etidronate Disodium.
As of Nov 20, 2026, ANDA 75800 (Etidronate Disodium), held by PharmoBedient, was first approved by FDA on Jan 24, 2003, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 24, 2003 | Original application | Approved | None posted |
| Etidronate Disodium200MG · tablet;oral | Etidronate Disodium | Discontinued |
| Etidronate Disodium400MG · tablet;oral | Etidronate Disodium | Discontinued |
| Jul 15, 2015 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jul 15, 2015 | Supplement 10Labeling · Standard review | Approved | None posted |
| Feb 19, 2010 | Supplement 7Labeling | Approved | None posted |
| Aug 29, 2006 | Supplement 5Labeling | Approved | None posted |
| Apr 5, 2005 | Supplement 2Labeling | Approved | None posted |
| Jan 24, 2003 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters